Hangzhou, Zhejiang, China Zheshang Industrial Integration Asset Management is the famous VC, which was founded in 2015. The leading representative office of defined VC is situated in the Hangzhou. The fund was located in Asia if to be more exact in China.
The real fund results show that this VC is 13 percentage points more often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2018. The fund is generally included in less than 2 deals every year.
The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Zheshang Industrial Integration Asset Management, startups are often financed by Zhejiang Xianju Pharmaceutical, Guangzhou YUEXIU Industrial Investment Fund, GoldStone Investment. The meaningful sponsors for the fund in investment in the same round are Share Capital, Sangel Capital, Jiuyou Capital.
For fund there is no match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Biopharma, Biotechnology. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline ZYXR.com, Denovo Biopharma
Related Funds
| Fund Name | Location |
| Arco Partners | Japan, Tokyo |
| Beiguang Wenzi Gehua Fund | - |
| Beijing Yibaiqi Keji Fuwu Youxian Gongsi | Beijing, Beijing, China |
| Cadence Design Systems | California, San Jose, United States |
| Edible Ventures | Boston, Massachusetts, United States |
| Ever Stream | - |
| Lawrence Asset Mangement | - |
| Mirae Asset-Naver Asia Growth Fund | - |
| ZKB Pharma Vision Fund | Switzerland, Zürich, Zurich |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Denovo Biopharma | $46M | 31 Oct 2019 | San Diego, California, United States | ||
ZYXR.com | $7M | 24 Jul 2018 | Shenzhen, Guangdong, China | ||
Compass Biotechnology | 16 May 2018 | Edmonton, Canada |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Denovo Biopharma | $46M | 31 Oct 2019 | San Diego, California, United States | ||
ZYXR.com | $7M | 24 Jul 2018 | Shenzhen, Guangdong, China | ||
Compass Biotechnology | 16 May 2018 | Edmonton, Canada |
